Fetterman: Congress Should 'Stop Dicking Around' on Weed

Photo by 1778011 via Pixabay.

Senator John Fetterman doesn't do subtlety, and he didn't start now. On July 21, 2026, the Pennsylvania Democrat told Congress in characteristically blunt terms to stop dragging its feet on marijuana reform, saying lawmakers need to "stop dicking around and make weed legal." It's the kind of line that gets clipped and shared, and it landed just five days after Senate Minority Leader Chuck Schumer, alongside Cory Booker and Ron Wyden, reintroduced the Cannabis Administration and Opportunity Act on July 16.

The timing wasn't an accident. Fetterman's remarks read like a plain-spoken gut check on a bill that, for all its policy ambition, is walking into Congress for the third time with basically the same odds of passing as the first two attempts: slim to none. That tension -- a senator saying the quiet part out loud while the legislative machinery grinds toward another dead end -- is really the story here.

What Fetterman Actually Said

Photo by Yunus Erdogdu via Pexels.

Fetterman's statement wasn't a one-off soundbite designed for cable news. He's been consistent on this for years, and his July 21 comments just sharpened the tone. He said he's "always been very pro-weed" and made clear he's not interested in moralizing about who uses cannabis or why, saying he won't judge anyone reaching for it to "knock the edge off of life." That's a notably casual, human way for a sitting U.S. senator to talk about a Schedule I substance, and it's part of why his commentary tends to travel further than more careful statements from colleagues.

He also gave credit where he thinks it's due, praising both the Biden administration's clemency actions and pardon initiatives and the Trump administration's more recent cannabis-related moves, while insisting that executive action alone isn't enough. In Fetterman's framing, presidents can only bend federal cannabis policy so far through pardons, scheduling reviews, and enforcement priorities -- actual legalization has to come from Congress writing new law, not from agencies reinterpreting old law.

This isn't a new position for him. Back in 2024, Fetterman sent a letter pushing the DEA to move faster on descheduling marijuana entirely rather than settling for a rescheduling compromise. And the advocacy goes back further than his Senate seat: as Pennsylvania's lieutenant governor, he toured all 67 counties holding listening sessions on legalization and was an outspoken champion of pardons for low-level cannabis offenses. The July 21 comments are less a new stance than a louder version of one he's held for the better part of a decade.

Inside the Cannabis Administration and Opportunity Act

Photo by Kindel Media via Pexels.

The bill Fetterman is needling Congress about is the Cannabis Administration and Opportunity Act, filed Thursday, July 16, 2026, with Schumer, Booker and Wyden as the lead sponsors. It arrived with 14 additional Democratic cosponsors, including Elizabeth Warren, Kirsten Gillibrand, Ed Markey, Patty Murray, Raphael Warnock and John Hickenlooper -- a roster that signals strong support within the Democratic caucus but says nothing about Republican buy-in, which the bill still doesn't have in any meaningful way.

Substantively, CAOA is ambitious. It would fully remove marijuana from the Controlled Substances Act rather than simply shifting it to a lower schedule, and it would build a federal regulatory framework around it, putting the Treasury Department's Alcohol and Tobacco Tax and Trade Bureau in charge of oversight with FDA-style labeling requirements layered on top. The bill also funds cannabis research, ends federal benefits discrimination tied to marijuana use, adds worker protections, and directs cannabis tax revenue back into communities hit hardest by decades of drug war enforcement.

There are practical pieces too. The bill directs the Department of Transportation to establish standards for cannabis-impaired driving and tasks the National Highway Traffic Safety Administration with collecting data on it -- an area where federal guidance has lagged badly behind state legalization. It also takes on the messy hemp-derived THC product market, aiming to head off a blanket ban that's been floated in other legislative vehicles and that the hemp industry has been bracing for.

Third Time Around, Same Committee Graveyard

Photo by Héctor Berganza via Pexels.

Here's the part that tempers all that ambition: this is CAOA's third formal introduction since 2022, and the first two never got anywhere close to a floor vote. The most recent prior version was filed as S.4226 on May 1, 2024, and it went the way of its predecessor -- referred to committee and left there, no hearing, no markup, no momentum.

The structural problem is straightforward. Schumer is Senate Minority Leader now, not Majority Leader, which means he doesn't control the floor calendar. A bill from the minority leader, however well-crafted, doesn't get scheduled for a vote unless the majority decides it's worth their time, and there's no indication that's happening this Congress. Committee referral without leadership backing from the majority side is essentially a bill on ice.

Advocates and outside analysts alike have started describing CAOA less as a serious legislative vehicle and more as a messaging bill -- a way for Senate Democrats to stake out a position, put cosponsors' names on record, and keep the issue alive in the news cycle while everyone involved understands it isn't going to become law under current conditions. That doesn't make it meaningless; reintroducing a bill repeatedly keeps pressure building and keeps the policy conversation from going stale. But it does mean readers shouldn't mistake reintroduction for progress toward passage.

How CAOA Collides With DEA Rescheduling

Photo by rosanna17 via Pixabay.

What makes the timing of CAOA's reintroduction interesting is that it's colliding with a federal cannabis policy shift that's already happened through the executive branch. In April 2026, Acting Attorney General Todd Blanche issued an order moving FDA-approved, state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act -- a move that had been in the works, in one form or another, since the rescheduling review process kicked off years earlier.

That order isn't settled law, though. Legal challenges to the April rescheduling decision are currently pending before the U.S. Court of Appeals for the D.C. Circuit, and how that litigation resolves will shape how meaningfully rescheduling actually changes things on the ground -- for research access, banking, and the tax treatment issues that have plagued state-licensed cannabis businesses under IRS code section 280E.

CAOA, notably, would make all of that litigation irrelevant if it were ever signed into law. Removing marijuana from the CSA entirely eliminates the scheduling question altogether -- there's no Schedule III designation to litigate if the substance isn't on any schedule. That sets up a split-track picture of federal cannabis policy right now: an executive branch process that's actually moved and is being fought out in court, running parallel to a congressional process that keeps reintroducing bold legislation with no realistic path to a vote. Both tracks are technically "progress," but they're operating on wildly different timelines and levels of actual traction.

NORML and the Public Opinion Argument

Photo by Gustavo Fring via Pexels.

NORML wasted no time backing the bill, issuing a formal endorsement shortly after its reintroduction. Political Director Morgan Fox framed the case in terms of public opinion and evidence rather than partisan politics, describing federal prohibition as increasingly out of step with public opinion, state laws, and scientific evidence.

Fox's point about jurisdictions is worth sitting with: nearly all Americans now live somewhere with some form of legal cannabis on the books, whether that's a medical program or full adult-use legalization. That's the gap NORML keeps hammering on -- state legislatures and voters have moved decisively over the past decade, while federal law has stayed frozen in a prohibition framework that increasingly looks like an outlier rather than the norm. It's a compelling argument for reform, even if it doesn't change vote math in a closely divided Senate.

Fetterman's frustration isn't really about one bill or one bad week in Washington. It's a symptom of a pattern that's repeated itself for years now: federal cannabis reform keeps advancing symbolically -- another reintroduction, another round of cosponsors, another round of press coverage -- while structurally stalling in a Congress too closely divided and too preoccupied to move it. CAOA's third trip through the introduction process is proof of concept for that pattern, not a break from it.

If you're looking for where actual near-term change in federal cannabis policy is likely to come from, it's probably not a bill with Schumer's name on it while he's leading the minority. It's more likely to come out of the D.C. Circuit, where the legal challenges to April's Schedule III rescheduling order are being sorted out right now. That litigation has a real mechanism for producing a binding outcome one way or the other, which is more than can be said for a bill sitting in committee.

None of this changes what actually governs cannabis legality day to day, which is state law. Whatever happens in the Senate or the courts, the rules for possession, purchase, and use vary widely from state to state and country to country, and they can change on legislative or regulatory timelines that have nothing to do with Congress. Anyone reading this should check their own state's current cannabis laws directly rather than assuming a Washington headline changes anything about what's legal where they live.